Shares of other companies:
A.O. Smith: Great Company, Inferior Investment
May 18, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
ALKS Stock News and Mentions of Alkermes plc Stocktwits
Updated: May 20, 2024 (09:13)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Alkermes Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Alkermes plc (ALKS).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Alkermes stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Alkermes plc (ALKS)
May 5, 2024 (10:55) / "Stocknews.com" (by Defense World Staff)
Alkermes ( NASDAQ:ALKS ) Downgraded by StockNews.com
Alkermes ( NASDAQ:ALKS - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued on Friday. Other equities research analysts have also issued reports about the company.
In Article Trend: Somewhat-Bullish
May 2, 2024 (15:39) / "Zacks Commentary" (by Zacks Equity Research)
Alkermes' ( ALKS ) Q1 Earnings & Revenues Fall Shy of Estimates
Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
In Article Trend: Neutral
May 1, 2024 (12:30) / "Zacks Commentary" (by Zacks Equity Research)
Alkermes ( ALKS ) Q1 Earnings and Revenues Miss Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of -25.42% and 2.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
May 1, 2024 (11:00) / "PR Newswire" (by Alkermes plc)
Alkermes plc Reports First Quarter 2024 Financial Results
- First Quarter Revenues of $350.4 Million - - GAAP Net Income from Continuing Operations of $38.9 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.23 - - Company Reiterates 2024 Financial Expectations -
In Article Trend: Neutral
April 30, 2024 (21:45) / "Motley Fool" (by Motley Fool Transcribing)
Harmony Biosciences ( HRMY ) Q1 2024 Earnings Call Transcript
HRMY earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
April 24, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Deciphera Pharmaceuticals, Inc. ( DCPH ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Deciphera Pharmaceuticals (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Somewhat-Bullish
April 22, 2024 (18:14) / "Zacks Commentary" (by Zacks Equity Research)
Will Alkermes' ( ALKS ) Proprietary Drugs Aid Amid Competition?
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
In Article Trend: Somewhat-Bullish
April 17, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Alkermes ( ALKS ) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Somewhat-Bullish
April 16, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
In Article Trend: Bullish
April 11, 2024 (14:15) / "Zacks Commentary" (by Zacks Equity Research)
Alkermes' ( ALKS ) ALKS 2680 Betters Wakefulness in Phase Ib Study
Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.
In Article Trend: Somewhat-Bullish
April 10, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
Why Alkermes ( ALKS ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In Article Trend: Bullish
April 9, 2024 (18:23) / "Benzinga" (by Vandana Singh)
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says - Alkermes ( NASDAQ:ALKS )
On Tuesday, Alkermes plc ALKS revealed topline results from the narcolepsy type 2 ( NT2 ) and idiopathic hypersomnia ( IH ) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680 for narcolepsy.
In Article Trend: Somewhat-Bullish
April 2, 2024 (16:10) / "Zacks Commentary" (by Zacks Equity Research)
Why Alkermes ( ALKS ) is Poised to Beat Earnings Estimates Again
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
In Article Trend: Somewhat-Bullish
March 26, 2024 (11:00) / "GlobeNewswire" (by Inc.)
Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company announces Q4 and YE 2023 financial results and provides business update.
In Article Trend: Neutral
March 26, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Invesco S&P SmallCap Health Care ETF ( PSCH ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
In Article Trend: Bullish
March 25, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
Hoth Therapeutics, Inc. (HOTH)
SmileDirectClub, Inc. (SDC)
Pasithea Therapeutics Corp. (KTTA)
Calliditas Therapeutics AB (publ) (CALT)
Oramed Pharmaceuticals Inc. (ORMP)
Teladoc Health, Inc. (TDOC)
Intuitive Surgical, Inc. (ISRG)
Kodiak Sciences Inc. (KOD)
BioNTech SE (BNTX)
Bausch + Lomb Corporation (BLCO)
This website uses cookies to ensure you get the best experience on our website